EULAR 2024 JAK/TYK Daily Topic Podcasts

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria:OP0195 Sonelokimab IL 17 A/F nanobody inhibitorLB0005 Izokibep IL17A nanobody inhibitorPOS0803 Vunakizumab, another IL17A inhibitorOP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib Giant Cell Arteritis and Polymyalgia Rheumatica UpdateDr. Janet Pope discusses abstracts LBA0001, OP0233, OP0261 and POS0280 at Eular 2024 in Vienna, Austria. JAK Inhibitors for New IndicationsDr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria. Pain in RA: Different Drugs for Different MechanismsDr. Aurelie Najm reports from Eular 2024 in Vienna, Austria, about abstracts OP0072 and OP0086. Top 3 Messages About JAK Inhibitor SafetyDr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety. DMARDs and Herpes Zoster Vaccination: To Stop or Not To StopDr. Jonathan Kay discusses abstracts POS0620 and OP0020 presented at Eular 2024 in Vienna, Austria. Has JAK POT Hit the Spot About Infection Risk?Dr. Yuz Yusof discusses abstract OP0092 presented at Eular 2024 in Vienna, Austria. Select your GCA TherapyDr. David Liew discusses LBA0001 presented at Eular 2024 in Vienna, Austria.